The term "cautious optimism" best describes the present situation regarding the anti-viral drug Remdesiver. As its manufacturer, Gilead Sciences, is emphasising:
"The totality of the data need to be analyzed in order to draw any conclusions from the trial. Anecdotal reports, while encouraging, do not provide the statistical power necessary to determine the safety and efficacy profile of remdesivir as a treatment for Covid-19," Gilead said.
Amongst the better news on the COVID-19 front is that this drug is one of a number currently being trialled. Should Remdesiver not live up to promise, the fight to develop an effective COVID-19 treatment is far from over.